​About Us

​Vast Therapeutics is a development-stage pharmaceutical company that develops therapies to treat resistant bacteria and enable patients suffering from severe respiratory diseases to breathe better and live life more fully.

Learn More

​Technology

​Vast Therapeutics’ solutions will provide cystic fibrosis patients with a convenient and effective inhalable treatment for drug-resistant respiratory infections.

​

Learn More

​Investors

​We are committed to bring breakthrough antimicrobial therapies to market that address the growing needs of patients with severe lung diseases like cystic fibrosis.

​

Learn More

RECENT NEWS

​Vast Therapeutics Receives Qualified Infectious Disease Product Status for BIOC11

Oct 8, 2019

DURHAM, NC – October 8, 2019 – Vast Therapeutics, Inc., a subsidiary of KNOW Bio, LLC, today announced that another of its drug candidates, BIOC11, has been designated as a “Qualified Infectious
Disease Product” (QIDP) by the U.S. Food and Drug Administration. 
​

Learn More

​KNOW Bio Announces Closing of $30 Million in Equity Financing

May 15, 2019

DURHAM, N.C., May 15, 2019 /PRNewswire/ -- KNOW Bio, LLC, (the Company or KNOW Bio), an RTP based conglomerate of biotechnology and MedTech companies, announced today that the Company has completed its next round of financing with a single investor, Reedy Creek Investments, LLC (Reedy Creek).

Learn More

​Vast Therapeutics Announces Results Showing Ability to Eradicate Anthrax
​
Jan 9, 2019

DURHAM, N.C., Jan. 9, 2019 /PRNewswire/ — Vast Therapeutics, Inc. (the Company), a preclinical stage pharmaceutical company delivering nitric oxide in a powder-based form, announced today that the Company’s drug candidate, BIOC51, is active against Bacillus anthracis, commonly known as anthrax, in an in vitro study carried out at Lovelace Biomedical …

Learn More